Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number Filing Date		10661196
			2003-09-12
	First Named Inventor	Ayma	n Mostafa
	Art Unit		2618
	Examiner Name	Raym	nond S. Dean
	Attorney Docket Number		037-0001

	U.S.PATENTS				Remove		
Examiner Initial*	Cite No Patent Number		Kind Code ¹ Issue Date		Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	6535732 2003-03-18		McIntosh et al.			
	2	6801767		2004-10-05	Schwartz et al.		
	3	6826163		2004-11-30	Mani et al.		
	4	6831901		2004-12-14	Millar		
If you wish to add additional U.S. Patent citation information please click the Add button.							
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	20030007214		2003-01-09	Aburakawa et al.		
	2	20040037565		2004-02-26	Young et al.		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10661196	
Filing Date		2003-09-12	
First Named Inventor	Ayman Mostafa		
Art Unit		2618	
Examiner Name Raym		ond S. Dean	
Attorney Docket Number		037-0001	

Date Considered

	3	20040198451	2004-10	0-07	Varghese			
If you wis	If you wish to add additional U.S. Published Application citation information please click the Add button. Add							
			FOREI	GN PAT	TENT DOCUM	ENTS	Remove	
Examiner Cite Foreign Document Country Number³ Code² į			Kind Code ⁴	Publication Date	Name of Patentee o Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	TS	
	1							
If you wish to add additional Foreign Patent Document citation information please click the Add button Add							•	
NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* No (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							T5	
	1							
If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE								

Specifical Codes of USPTO Potent Discussed as special SSTIG_CODY or METC 901.64. Edited rotion that issued the document, by the lock-lefter code (NIPC) Solidad STIG. 37. September 2017 or Suppress potent or country in the special stress of the purpose to see in section of the purpose the series or seed process the series in section or the pulsed rotion. 4 Nicrol of occurrent by the appropriate symbols as indicated on the document under WIPC Standard ST.16 if possible. Applicant is to place a check mark here if English tanguages the resistation is attacked.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number			10661196	
	Filing Date		2003-09-12	
First Named Inventor Aymar		Ayma	n Mostafa	
	Art Unit		2618	
	Examiner Name	Raym	nond S. Dean	
	Attorney Docket Numb	ec	037-0001	

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the app	ropriate selection(s):
---------------	----------	-------------	--------------	------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) in

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Mark Zagorin/	Date (YYYY-MM-DD)	2007-03-13
Name/Print	Mark Zanorin	Registration Number	36067

This collection of information is required by 3T CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Box 1445, Alexandris, V.S. 2231-1450. D. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA.2231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.